Trending...
- CCHR Report Links 145 Violent Incidents to Psychiatric Drug Exposure, Urges National Oversight and Action
- $10 Million Annual Revenue Merger, Profitable Partner in AI Powered Specialty Automotive Sales Projected to Scale Above $200M: Stock Symbol: NWPG
- A Hidden Magical World Awaits in Ashley Gayheart's Upcoming Young Adult Fantasy, Rosewood Academy: The Awakening
DURHAM, N.C.--(BUSINESS WIRE)--Precision BioSciences, Inc. (Nasdaq: DTIL) a clinical stage gene editing company developing ARCUS®-based ex vivo allogeneic CAR T and in vivo gene editing therapies, today announced that the Company will participate in the H.C. Wainwright Cell Therapy Virtual Conference taking place February 28, 2023.
Details for the virtual fireside chat are as follows:
Date: Tuesday, February 28, 2023
Time: 2:00 PM ET
The fireside chat will be available via a live webcast accessible on Precision's website in the Investors section under Events & Presentations on February 28, 2023: https://investor.precisionbiosciences.com/events-and-presentations. An archived replay will be available for approximately 30 days following the event.
More on ncarol.com
About Precision BioSciences, Inc.
Precision BioSciences, Inc. is a clinical stage biotechnology company dedicated to improving life (DTIL) with its novel and proprietary ARCUS® genome editing platform. ARCUS is a highly precise and versatile genome editing platform that was designed with therapeutic safety, delivery, and control in mind. Using ARCUS, the Company's pipeline consists of multiple ex vivo "off-the-shelf" CAR T immunotherapy clinical candidates and several in vivo gene editing candidates designed to cure genetic and infectious diseases where no adequate treatments exist. For more information about Precision BioSciences, please visit www.precisionbiosciences.com.
Contacts
Investor Contact:
Mei Burris
Director, Investor Relations & Finance
Mei.burris@precisionbiosciences.com
Media Contact:
Maurissa Messier
Senior Director, Corporate Communications
Maurissa.Messier@precisionbiosciences.com
Details for the virtual fireside chat are as follows:
Date: Tuesday, February 28, 2023
Time: 2:00 PM ET
The fireside chat will be available via a live webcast accessible on Precision's website in the Investors section under Events & Presentations on February 28, 2023: https://investor.precisionbiosciences.com/events-and-presentations. An archived replay will be available for approximately 30 days following the event.
More on ncarol.com
- Michael H. Kaplan, Colorado Workers' Compensation Attorney, Rallies Athlete Unions Against Proposed Legislative "Carve-Outs"
- Viasat, Galaxy 1 Communications and L2 Aviation to bring avionics integration to Advanced Air Mobility
- OmniOrders Officially Launches Unified Commerce Operations Platform for Multi-Channel Retailers
- Fulton County DA Fani Willis Officially Endorses Dr. Heavenly Kimes + Black Economic Agenda
- Bellwether Farm Presents Kerry Hill Lamb to His Majesty King Charles III During Historic U.S. State Visit
About Precision BioSciences, Inc.
Precision BioSciences, Inc. is a clinical stage biotechnology company dedicated to improving life (DTIL) with its novel and proprietary ARCUS® genome editing platform. ARCUS is a highly precise and versatile genome editing platform that was designed with therapeutic safety, delivery, and control in mind. Using ARCUS, the Company's pipeline consists of multiple ex vivo "off-the-shelf" CAR T immunotherapy clinical candidates and several in vivo gene editing candidates designed to cure genetic and infectious diseases where no adequate treatments exist. For more information about Precision BioSciences, please visit www.precisionbiosciences.com.
Contacts
Investor Contact:
Mei Burris
Director, Investor Relations & Finance
Mei.burris@precisionbiosciences.com
Media Contact:
Maurissa Messier
Senior Director, Corporate Communications
Maurissa.Messier@precisionbiosciences.com
0 Comments
Latest on ncarol.com
- Postmortem Pathology, a leading provider of private autopsies, has announced its expansion into the Las Vegas market
- Kick'em Out Quick® Evictions Announces a New Endorsed Eviction Attorney in Atlanta / Fulton County, GA
- Why Athletic Recovery Begins in the Nervous System
- A Hidden Magical World Awaits in Ashley Gayheart's Upcoming Young Adult Fantasy, Rosewood Academy: The Awakening
- Scott Ritsema of Bisnar Chase Selected for 2026 National Traumatic Brain Injury Association
- Flint Youth Film Festival Shifts Gears, Becomes Vehicle City Film Festival
- 62% of Gen X have no estate planning documents — Trust & Will research identifies "the Sandwich Gap"
- Nayarit's Jungle Coast Redefines Luxury Travel on Mexico's Pacific Now More Accessible Than Ever
- $10 Million Annual Revenue Merger, Profitable Partner in AI Powered Specialty Automotive Sales Projected to Scale Above $200M: Stock Symbol: NWPG
- Virginia Moving Company Nearly Doubles Customer Calls in Two Weeks After Switching to CARL — the Bold New Alternative to WordPress
- Crankshooter Names Christian DiMonda Director of Marketing to Lead Brand Growth & Community Strategy
- RAS AP Consulting Launches Vendor Master File & Payment Controls Assessment for NACHA Phase 2 Compliance
- Living Waters Inc Announces the Passing of Founder and Former President & CEO Lawrence Barker-Bey, Jr
- New Homesites Released at Heritage at Manalapan Featuring Scenic Golf Course Views
- The Ultimate Solution to Halt Thermal Runaway
- Strategic Talent Associates Launches THE ALIGNED RESET™
- Calvetta Phair Founder & CEO Earns AOPA Foundation Flight Training Scholarship, Inspiring a New Generation of STEM Dreamers in Underserved Communities
- 40 Years Strong: IMI Association Executives Expands Impact in a Changing Nonprofit Landscape
- MTV EMA Nominee and WOA Founder Oliver Sean Conferred Doctor of Musical Arts (DMA) Degree
- Karen D. Gentry Announces New Book Focused on Relationships and Personal Growth